252 related articles for article (PubMed ID: 23293352)
1. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.
Bae J; Munshi A; Li C; Samur M; Prabhala R; Mitsiades C; Anderson KC; Munshi NC
J Immunol; 2013 Feb; 190(3):1360-71. PubMed ID: 23293352
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
[TBL] [Abstract][Full Text] [Related]
3. Geldanamycin-mediated inhibition of heat shock protein 90 partially activates dendritic cells, but interferes with their full maturation, accompanied by impaired upregulation of RelB.
Trojandt S; Reske-Kunz AB; Bros M
J Exp Clin Cancer Res; 2014 Feb; 33(1):16. PubMed ID: 24524692
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
Schnaider T; Somogyi J; Csermely P; Szamel M
Cell Stress Chaperones; 2000 Jan; 5(1):52-61. PubMed ID: 10701840
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
6. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.
Yorgin PD; Hartson SD; Fellah AM; Scroggins BT; Huang W; Katsanis E; Couchman JM; Matts RL; Whitesell L
J Immunol; 2000 Mar; 164(6):2915-23. PubMed ID: 10706677
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.
Bae J; Mitsiades C; Tai YT; Bertheau R; Shammas M; Batchu RB; Li C; Catley L; Prabhala R; Anderson KC; Munshi NC
J Immunol; 2007 Jun; 178(12):7730-7. PubMed ID: 17548610
[TBL] [Abstract][Full Text] [Related]
8. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
Morel E; Bellón T
J Immunol; 2008 Aug; 181(4):2368-81. PubMed ID: 18684926
[TBL] [Abstract][Full Text] [Related]
9. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
10. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells.
Mingari MC; Ponte M; Bertone S; Schiavetti F; Vitale C; Bellomo R; Moretta A; Moretta L
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1172-7. PubMed ID: 9448304
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes.
Schnaider T; Somogyi J; Csermely P; Szamel M
Life Sci; 1998; 63(11):949-54. PubMed ID: 9747895
[TBL] [Abstract][Full Text] [Related]
12. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.
Stuehler C; Mielke S; Chatterjee M; Duell J; Lurati S; Rueckert F; Einsele H; Bargou RC; Topp MS
Blood; 2009 Sep; 114(13):2829-36. PubMed ID: 19657113
[TBL] [Abstract][Full Text] [Related]
13. HSP90 is crucial for regulation of LAT expression in activated T cells.
Hayashi K; Kamikawa Y
Mol Immunol; 2011 Mar; 48(6-7):941-6. PubMed ID: 21251717
[TBL] [Abstract][Full Text] [Related]
14. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
16. CD8+ NK cells are predominant in chimpanzees, characterized by high NCR expression and cytokine production, and preserved in chronic HIV-1 infection.
Rutjens E; Mazza S; Biassoni R; Koopman G; Ugolotti E; Fogli M; Dubbes R; Costa P; Mingari MC; Greenwood EJ; Moretta L; De Maria A; Heeney JL
Eur J Immunol; 2010 May; 40(5):1440-50. PubMed ID: 20306468
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin.
Mori S; Jewett A; Cavalcanti M; Murakami-Mori K; Nakamura S; Bonavida B
Int J Oncol; 1998 May; 12(5):1165-70. PubMed ID: 9538144
[TBL] [Abstract][Full Text] [Related]
18. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes.
Poggi A; Tomasello E; Revello V; Nanni L; Costa P; Moretta L
Int Immunol; 1997 Sep; 9(9):1271-9. PubMed ID: 9310830
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.
Rossi LE; Avila DE; Spallanzani RG; Ziblat A; Fuertes MB; Lapyckyj L; Croci DO; Rabinovich GA; Domaica CI; Zwirner NW
J Leukoc Biol; 2012 Feb; 91(2):321-31. PubMed ID: 22124136
[TBL] [Abstract][Full Text] [Related]
20. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
